<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="117648">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01887769</url>
  </required_header>
  <id_info>
    <org_study_id>20824</org_study_id>
    <nct_id>NCT01887769</nct_id>
  </id_info>
  <brief_title>Body Composition Analysis for Patient With Lung Cancer Using Computed Tomography Image Analysis</brief_title>
  <acronym>BAT-SCAN</acronym>
  <sponsors>
    <lead_sponsor>
      <agency>Centre de Recherche de l'Institut Universitaire de Cardiologie et de Pneumologie de Quebec</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre de Recherche de l'Institut Universitaire de Cardiologie et de Pneumologie de Quebec</source>
  <oversight_info>
    <authority>Canada: Ethics Review Committee</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Rationale: With 1.6 million new cases diagnosed each year and 1.3 million deaths, lung
      cancer is the leading cancer-related death worldwide and it represents a pressing health
      issue. Patients with lung cancer are more likely to experience cachexia, a severe
      debilitating disorder causing fatigue, weight loss, muscle wasting and associated with
      reduced physical function, increased chemotherapy toxicity and reduced survival. This
      syndrome occurring in about 80% of advanced cancer patients is the direct cause of death in
      about 20% of cases. However, despite the importance of cachexia in lung cancer, it has been
      mainly studied from several assessment methods which do not usually differentiate muscle
      from other tissues.

      Aim: To analyze body composition of patients with lung cancer at diagnosis using computed
      tomography (CT-Scan) image analysis.

      Methods: This is a retrospective study extending over a period of 3 years conducted at the
      Institut universitaire de cardiologie et de pneumologie de Québec (2009-2012).    We listed
      patients newly diagnosed with lung cancer who had a thoraco-abdominal CT-scan performed in
      our institution. Following the collection of clinical data from patient records, we used
      SliceOmatic software to quantify muscle area, visceral fat area and subcutaneous fat area
      from a single abdominal cross-sectional image at the level of the third lumbar vertebra.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>May 2012</start_date>
  <completion_date type="Anticipated">May 2015</completion_date>
  <primary_completion_date type="Anticipated">May 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Cohort, Time Perspective: Retrospective</study_design>
  <primary_outcome>
    <measure>Change of muscle area (cm2/m2) at the level of the third lumbar vertebra</measure>
    <time_frame>at the time of the diagnosis of lung cancer and one year following it.</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Change of fat area (cm2/m2) at the level of the third lumbar vertebra</measure>
    <time_frame>at the time of the diagnosis of lung cancer and one year following it.</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>days of survival</measure>
    <time_frame>From the time of the diagnosis of lung cancer until one year</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">1000</enrollment>
  <condition>Lung Cancer</condition>
  <arm_group>
    <arm_group_label>Lung cancer patient at diagnosis</arm_group_label>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Lung cancer patients, at diagnosis, following in oncology clinic
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Men or women

          -  Between 40-80 years of age

          -  Primary lung cancer diagnosed between 2009 and 2012

          -  CT-Scan done at the time of the diagnosis

        Exclusion Criteria:

          -  Chemotherapy, radiotherapy or surgery at the time of the first Ct-Scan image

          -  History of other cancer (during the last five years)
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Didier Saey, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre de Recherche de l'Institut Universitaire de Cardiologie et de Pneumologie de Quebec</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Institut universitaire de cardiologie et de pneumologie de Québec</name>
      <address>
        <city>Québec</city>
        <state>Quebec</state>
        <zip>G1V 4G5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Didier Saey, PhD</last_name>
      <phone>418-656-8711</phone>
      <phone_ext>2614</phone_ext>
      <email>didier.saey@criucpq.ulaval.ca</email>
    </contact>
    <investigator>
      <last_name>Didier Saey, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>June 2013</verification_date>
  <lastchanged_date>June 25, 2013</lastchanged_date>
  <firstreceived_date>February 13, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Centre de Recherche de l'Institut Universitaire de Cardiologie et de Pneumologie de Quebec</investigator_affiliation>
    <investigator_full_name>Didier Saey</investigator_full_name>
    <investigator_title>PhD</investigator_title>
  </responsible_party>
  <keyword>Lung cancer</keyword>
  <keyword>Body composition analysis</keyword>
  <keyword>Ct-Scan</keyword>
  <keyword>Muscle mass</keyword>
  <keyword>Cachexia</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Lung Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
